US 12,358,969 B2
CTLA-4 variant immunomodulatory proteins and uses thereof
Lawrence Evans, Seattle, WA (US); Joseph L. Kuijper, Seattle, WA (US); and Ryan Swanson, Seattle, WA (US)
Assigned to Alpine Immune Sciences, Inc., Seattle, WA (US)
Filed by Alpine Immune Sciences, Inc., Seattle, WA (US)
Filed on Jul. 20, 2023, as Appl. No. 18/355,539.
Application 18/355,539 is a continuation of application No. 16/755,072, granted, now 11,753,458, previously published as PCT/US2018/055095, filed on Oct. 9, 2018.
Claims priority of provisional application 62/733,615, filed on Sep. 19, 2018.
Claims priority of provisional application 62/613,379, filed on Jan. 3, 2018.
Claims priority of provisional application 62/570,619, filed on Oct. 10, 2017.
Prior Publication US 2024/0158463 A1, May 16, 2024
Int. Cl. C07K 14/705 (2006.01); A61K 47/65 (2017.01); A61P 19/02 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/00 (2006.01)
CPC C07K 14/70521 (2013.01) [A61K 47/65 (2017.08); A61P 19/02 (2018.01); C07K 14/7051 (2013.01); C12N 5/0637 (2013.01); C12N 15/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)] 37 Claims
 
1. An immunomodulatory Fc fusion polypeptide comprising,
(i) a variant CTLA-4 polypeptide comprising the modifications L63P and Y105L, wherein the variant CTLA-4 polypeptide amino acids are numbered with reference to SEQ ID NO:2;
(ii) a first peptide linker;
(iii) an Fc region;
(iv) a second peptide linker;
(v) a portion of a second immunoglobulin superfamily (IgSF) protein, wherein the portion comprises the IgV domain of a PD-L1 protein.